Skip to main content
. 2019 Dec 21;8:204. doi: 10.1186/s13756-019-0652-x

Fig. 5.

Fig. 5

Results from probabilistic sensitivity analysis for CAZ-AVI sequence vs. Ceftolozane/Tazobactam sequence, on cost-effectiveness acceptability curve.

Abbreviations: CAZ-AVI ceftazidime-avibactam, QALY quality-adjusted life year.

CAZ-AVI sequence: CAZ-AVI plus metronidazole, followed by colistin + tigecycline + high-dose meropenem.

Ceftolozane/tazobactam sequence: Ceftolozane/tazobactam plus metronidazole, followed by colistin + tigecycline + high-dose meropenem